BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dong J, Yu XF, Zou J. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: A meta-analysis. World J Gastroenterol 2009; 15(48): 6102-6110 [PMID: 20027685 DOI: 10.3748/wjg.15.6102]
URL: https://www.wjgnet.com/1007-9327/full/v15/i48/6102.htm
Number Citing Articles
1
Tai‐Cherng Liou, Po‐Hao Liao, Yu‐Chun Lin, Cheng‐Hsin Chu, Shou‐Chuan Shih. Intraluminal therapy for Helicobacter pylori infectionJournal of Gastroenterology and Hepatology 2019; 34(8): 1337 doi: 10.1111/jgh.14627
2
David Y. Graham. Helicobacter pylori Eradication Therapy Research: Ethical Issues and Description of ResultsClinical Gastroenterology and Hepatology 2010; 8(12): 1032 doi: 10.1016/j.cgh.2010.07.002
3
Mohammad Reza Esmaeili-Dooki, Hossein Shirdel, Mahmood Hajiahmadi. Eradication of Helicobacter pylori in Children by Triple Therapy Regimens of Amoxicillin, Omeprazole, and Clarithromycin or AzithromycinIranian Journal of Pediatrics 2015; 25(6) doi: 10.5812/ijp.2360
4
Ariolana A dos Santos, Adriana A Carvalho. Pharmacological therapy used in the elimination of <italic>Helicobacter pylori</italic> infection: A reviewWorld Journal of Gastroenterology 2015; 21(1): 139-154 doi: 10.3748/wjg.v21.i1.139
5
Yiqiao Xin, Jan Manson, Lindsay Govan, Robin Harbour, Jenny Bennison, Eleanor Watson, Olivia Wu. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysisBMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0491-7
6
M. Escobedo-Belloc, F. Bosques-Padilla. The rise of antibiotic resistance to Helicobacter pylori in Mexico: Is azithromycin plus levofloxacin the answer?Revista de Gastroenterología de México (English Edition) 2019; 84(3): 271 doi: 10.1016/j.rgmxen.2018.10.006
7
Ling Ren, Hong Lu, Hai Yan Li, Ling Yin Zhu, Xiao Qing Xu, Li Yang Gu, Zhi Zheng Ge, Xiao Bo Li. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, ChinaJournal of Digestive Diseases 2014; 15(11): 622 doi: 10.1111/1751-2980.12186
8
M. Escobedo-Belloc, F. Bosques-Padilla. El incremento en la resistencia de Helicobacter pylori a los antibióticos en México: ¿son la azitromicina más levofloxacina la respuesta?Revista de Gastroenterología de México 2019; 84(3): 271 doi: 10.1016/j.rgmx.2018.10.005
9
Asma Nizam, Zao Iman Chaudary, Saad Ali Ahmad, Nimra Nawaz, Zainab Riaz, Aamir Shehzad, Muhammad Irfan Jamil. Comparison of the Efficacy of Two-Week Vonoprazan Versus Lansoprazole-Based Quadruple Sequential Antibiotic Therapy in Eradicating Helicobacter pylori Infection: A Non-randomized Clinical TrialCureus 2024;  doi: 10.7759/cureus.52758
10
Antibacterial Agents2012; : 173 doi: 10.1002/9781118325421.ch8
11
Seung Won Ra, Marc A. Sze, Eun Chong Lee, Sheena Tam, Yeni Oh, Nick Fishbane, Gerard J. Criner, Prescott G. Woodruff, Stephen C. Lazarus, Richard Albert, John E. Connett, Meilan K. Han, Fernando J. Martinez, Shawn D. Aaron, Robert M. Reed, S. F. Paul Man, Don D. Sin. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori Respiratory Research 2017; 18(1) doi: 10.1186/s12931-017-0594-x